var data={"title":"Pegylated interferon (peginterferon) alfa-2a: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pegylated interferon (peginterferon) alfa-2a: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6732?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pegylated-interferon-peginterferon-alfa-2a-drug-information\" class=\"drug drug_general\">see &quot;Pegylated interferon (peginterferon) alfa-2a: Drug information&quot;</a> and <a href=\"topic.htm?path=pegylated-interferon-peginterferon-alfa-2a-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pegylated interferon (peginterferon) alfa-2a: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709197\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risk of serious disorders:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon alfa-2a may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Monitor patients closely with periodic clinical and laboratory evaluations. Withdraw therapy in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all, cases, these disorders resolve after stopping peginterferon alfa-2a therapy.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206899\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Pegasys;</li>\n      <li>Pegasys ProClick</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206900\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Pegasys</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1029834\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Interferon</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1029863\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=pegylated-interferon-peginterferon-alfa-2a-drug-information\" class=\"drug drug_general\">see &quot;Pegylated interferon (peginterferon) alfa-2a: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children &ge;5 years and Adolescents: <b>Chronic hepatitis C virus (HCV) infection:</b> SubQ: 104 mcg/m<sup>2</sup> once weekly; maximum dose: 180 mcg; in combination with ribavirin (Copegus) (Schwartz, 2011); <b>Note:</b> Dosing presented is mathematically equivalent to weekly dosing presented in manufacturer&rsquo;s labeling: 180 mcg/1.73 m<sup>2</sup> x Body Surface Area (BSA); adolescents who reach their 18th birthday during treatment should remain on the pediatric regimen</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Duration of therapy (based on genotype):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Genotype 1, 4, 5, 6: 48 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Genotype 2, 3: 24 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic hepatitis B:</b> SubQ: 180 mcg once weekly for 48 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic hepatitis C virus (HCV) infection (monoinfection or coinfection with HIV):</b> SubQ: 180 mcg once weekly for 48 weeks as monotherapy or in combination with ribavirin (Copegus&reg;)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Duration of therapy: Monoinfection (based on genotype):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Genotypes 1, 4: 48 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Genotypes 2, 3: 24 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Genotypes 5, 6: No dosing recommendations provided; data insufficient</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">Duration of therapy: Coinfection with HIV: 48 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> American Association for the Study of Liver Diseases (AASLD) guidelines recommendation: Adults with chronic HCV infection (Ghany, 2009): Treatment of choice: Ribavirin plus <b>peginterferon</b>; clinical condition and ability of patient to tolerate therapy should be evaluated to determine length and/or likely benefit of therapy. Recommended treatment duration (AASLD guidelines): Genotypes 1,4: 48 weeks; Genotypes 2,3: 24 weeks; Coinfection with HIV: 48 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents: There are no dosage adjustment provided in manufacturer's labeling; has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;30 mL/minute: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute: Reduce dose to 135 mcg weekly; monitor for interferon toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">End-stage renal disease (ESRD) requiring hemodialysis: 135 mcg weekly; monitor for interferon toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for hepatic impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;5 years and Adolescents: <i>Chronic Hepatitis C:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ALT &ge;5 but &lt;10 x ULN: Decrease interferon dose to 78 mcg/m<sup>2</sup> once weekly. Monitor weekly; further modify dose if needed until ALT stabilizes or decreases (Schwartz, 2011). <b>Note:</b> Dosing presented is mathematically equivalent to adjusted weekly dose in manufacturer&rsquo;s labeling: 135 mcg/1.73 m<sup>2</sup> x Body Surface Area (BSA)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ALT &ge;10 x ULN (persistent): Discontinue interferon</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Chronic hepatitis C (HCV)</i>: ALT progressively rising above baseline: Decrease dose to 135 mcg weekly <b>and</b> monitor LFTs more frequently. If ALT continues to rise despite dose reduction or ALT increase is accompanied by increased bilirubin or hepatic decompensation, discontinue therapy immediately. Therapy may resume after ALT flare subsides.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Chronic hepatitis B (HBV): </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ALT &gt;5 x ULN: Consider decreasing dose to 135 mcg weekly or temporarily discontinuing (may resume after ALT flare subsides) <b>and</b> monitor LFTs more frequently. If ALT continues to rise despite dose reduction or ALT increase is accompanied by increased bilirubin or hepatic decompensation, discontinue therapy immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ALT &gt;10 x ULN: Consider discontinuing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity: </b> <b>Note:</b> Pediatric dosing adjustments shown below correspond to the following doses in manufacturer's labeling: 78 mcg/m<sup>2</sup> = 135 mcg/1.73 m<sup>2</sup>; 52 mcg/m<sup>2</sup> = 90 mcg/1.73 m<sup>2</sup>; and 26 mcg/m<sup>2</sup> = 45 mcg/1.73 m<sup>2</sup> (Schwartz, 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>For moderate to severe adverse reactions:</i> Children &ge;5 years and Adolescents: Decrease to 78 mcg/m<sup>2</sup> once weekly for initial dose reduction; further dose reductions to 52 mcg/m<sup>2</sup> once weekly and then 26 mcg/m<sup>2</sup> once weekly may be necessary in some cases if reaction persists or recurs. Up to three dosing adjustments for toxicity may be made before discontinuation is considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Depression (severity based upon DSM-IV criteria):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild depression: Children &ge;5 years and Adolescents: No dosage adjustment required; evaluate once weekly by visit/phone call. If depression remains stable, continue weekly visits. If depression improves, resume normal visit schedule.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate depression: Children &ge;5 years and Adolescents: Initially decrease interferon dose to 78 mcg/m<sup>2</sup> once weekly and based upon response of adverse effect further dose modifications may be necessary in stepwise approach; next decrease to 52 mcg/m<sup>2</sup> once weekly and then 26 mcg/m<sup>2</sup> once weekly; evaluate once weekly with an office visit at least every other week. If symptoms improve and remain stable for 4 weeks, resume normal visit schedule; may continue reduced dosing or return to normal dose. If depression remains stable, consider psychiatric evaluation and continue reduced dosing. If symptoms worsen, considered further dosage reduction; discontinue therapy if no improvement after three dosage reductions.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe depression: Children &ge;5 years and Adolescents: Discontinue interferon permanently. Obtain immediate psychiatric consultation. Discontinue ribavirin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Based on hematological parameters:</i> <b>Note:</b> Management dependent upon weeks of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;5 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Neutropenia:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">ANC 750-999/mm<sup>3</sup>:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Week 1-2: Decrease dose to 78 mcg/m<sup>2</sup> once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weeks 3-48: No modification</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">ANC 500-749/mm<sup>3</sup>:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Week 1-2: Hold dose until ANC &gt;750/mm<sup>3</sup> then resume therapy at 78 mcg/m<sup>2</sup> once weekly. Assess WBC weekly for 3 weeks to verify ANC &gt;750/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weeks 3-48: Decrease dose to 78 mcg/m<sup>2</sup> once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">ANC 250-499/mm<sup>3</sup>:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Week 1-2: Hold dose until ANC &gt;750/mm<sup>3</sup> then resume dose at 52 mcg/m<sup>2</sup> once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Weeks 3-48: Hold dose until ANC &gt;750/mm<sup>3</sup> then resume dose at 78 mcg/m<sup>2</sup> once weekly</p>\n    <p style=\"text-indent:-4em;margin-left:12em;\">ANC &lt;250/mm<sup>3</sup> or febrile neutropenia: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Thrombocytopenia: Platelet count &lt;50,000/mm<sup>3</sup>: Decrease dose to 52 mcg/m<sup>2</sup> once weekly</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206881\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pegasys: 180 mcg/mL (1 mL); 180 mcg/0.5 mL (0.5 mL) [contains benzyl alcohol, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pegasys ProClick: 135 mcg/0.5 mL (0.5 mL) [contains benzyl alcohol, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pegasys ProClick: 180 mcg/0.5 mL (0.5 mL) [contains benzyl alcohol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206867\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874941\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088679.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRlRq+irVTCmIpmoyMaJtVyuA==&amp;TOPIC_ID=87809\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088679.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1029868\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Do not shake vial, prefilled syringe, or autoinjector. Allow syringe, autoinjector, or vial to reach room temperature before use; wait for condensation on the outside of the syringe or autoinjector to disappear before use. The vial may be warmed by gently rolling in the palms of the hand for ~1 minute. Allow the autoinjector to come to room temperature on its own for ~20 minutes; do not warm autoinjector any other way. Do not use if solution contains particulate matter or is discolored.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Administer in the abdomen or thigh. Rotate injection site. Discard unused solution. Administration should be done on the same day and at approximately the same time each week. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206895\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store in refrigerator at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Do not leave out of the refrigerator for more than 24 hours. Do not freeze or shake. Protect from light. Discard any unused portion. The following stability information has also been reported:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intact vial: May be stored at room temperature for up to 14 days (Cohen, 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prefilled syringe: May be stored at room temperature for up to 6 days (Cohen, 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1029835\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chronic hepatitis C: Treatment of chronic hepatitis C virus (HCV) infection in patients with compensated liver disease and who have not been previously treated with interferon alfa alone or in combination with ribavirin (monotherapy with peginterferon alfa-2a is not recommended for treatment of chronic hepatitis C infection unless a patient has a contraindication to or significant intolerance of ribavirin) (FDA approved in ages &ge;5 years and adults); treatment of chronic hepatitis C virus (HCV) infection in patients with histological evidence of cirrhosis (Child-Pugh class A) and compensated liver disease (FDA approved in adults); treatment of  patients coinfected with HCV and clinically stable HIV disease (CD<sub>4</sub> count &gt;100 cells/mm<sup>3</sup>) (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Combination with ribavirin is indicated in patients with HCV genotypes other than 1, pediatric patients (5-17 years), or patients with HCV genotype 1 where use of an HCV NS3/4A protease inhibitor is not warranted based on tolerability, contraindications, or other clinical factors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Combination with ribavirin and an HCV NS3/4A protease inhibitor is indicated in adults with HCV genotype 1.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chronic hepatitis B: Treatment with hepatitis B e antigen (HBeAg)-positive and HBeAG-negative chronic hepatitis B virus (HBV) infection who have compensated liver disease and evidence of viral replication and liver inflammation (FDA approved in adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206924\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety (adults), depression (adults), dizziness (more common in adults), fatigue (more common in adults), headache, insomnia (adults), irritability (adults), lack of concentration (adults), memory impairment (adults), mood changes (adults), nervousness (adults), pain (adults), rigors (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia (more common in adults), dermatitis (adults), diaphoresis (adults), eczema (adults), pruritus (adults), skin rash, xeroderma (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Growth suppression (children and adolescents, percentile decrease [&ge;15 percentiles], weight and height), hyperthyroidism (adults), hypothyroidism (adults), weight loss (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia (adults), decreased appetite (children and adolescents), diarrhea (adults), nausea (more common in adults), vomiting (adults), xerostomia (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia (adults), lymphocytopenia (adults), neutropenia (adults), thrombocytopenia (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT (more common in adults, hepatitis B), increased serum AST (children and adolescents), liver decompensation (in CHC/HIV patients; adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Bacterial infection (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia (adults), back pain (adult), myalgia (adults), weakness (more common in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough (more common in children and adolescents), dyspnea (adults), epistaxis (children and adolescents), flu-like symptoms (children and adolescents), nasopharyngitis (children and adolescents), upper respiratory tract infection (children and adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Aggressive behavior, anaphylaxis, angina pectoris, angioedema, aplastic anemia, auditory impairment, autoimmune disorders, bipolar mood disorder, bronchiolitis obliterans, bronchoconstriction, cardiac arrhythmia, cerebral hemorrhage, chest pain, cholangitis, colitis, coma, corneal ulcer, dehydration, diabetes mellitus, dyspepsia, dyspnea on exertion, endocarditis, erythema multiforme major, exacerbation of hepatitis B, exfoliative dermatitis, gastrointestinal hemorrhage, graft rejection (hepatic, renal), hallucination, hearing loss, hematocrit decreased, hemoglobin decreased, hepatic insufficiency, hyperglycemia, hyperpigmentation, hypersensitivity reaction, hypertension, hypoglycemia, increased serum triglycerides, influenza, interstitial pneumonitis, limb abscess, liver steatosis, macular edema, mania, myocardial infarction, myositis, optic neuritis, pancreatitis, papilledema, peptic ulcer, peripheral neuropathy, pneumonia, psychiatric disturbance, psychosis, pulmonary embolism, pulmonary infiltrates, pure red cell aplasia, retinal cotton-wool spot, retinal detachment, retinal hemorrhage, retinal thrombosis (in artery or vein), retinopathy, rheumatoid arthritis, sarcoidosis, seizures, Stevens-Johnson syndrome, substance overdose, suicidal ideation, supraventricular arrhythmia, systemic lupus erythematosus, thrombotic thrombocytopenic purpura, tongue discoloration, urticaria, vesiculobullous reaction, vision loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206886\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity reactions (eg, urticaria, angioedema, bronchoconstriction, anaphylaxis, Stevens-Johnson syndrome) to peginterferon alfa-2a, other alfa interferons, or any component of the formulation; autoimmune hepatitis; hepatic decompensation in cirrhotic patients (Child-Pugh score &gt;6, class B and C) before treatment; hepatic decompensation with Child-Pugh score &ge;6 in cirrhotic CHC coinfected with HIV before treatment; neonates and infants (due to benzyl alcohol component)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Combination therapy with peginterferon alfa-2a and ribavirin is also contraindicated in pregnancy; men whose female partners are pregnant; patients with hemoglobinopathies (ie, thalassemia major, sickle cell disease); coadministration with didanosine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for interferons is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206870\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Causes bone marrow suppression, including potentially severe cytopenias; alfa interferons may (rarely) cause aplastic anemia. Ribavirin may potentiate these effects. When used in combination with ribavirin, use caution with baseline neutrophil count &lt;1,500/mm<sup>3</sup>, platelet count &lt;90,000/mm<sup>3</sup> or hemoglobin &lt;10 g/dL. Discontinue therapy (at least temporarily) if ANC &lt;500/mm<sup>3</sup> or platelet count &lt;25,000/mm<sup>3</sup>. Severe neutropenia and thrombocytopenia may occur with a greater incidence in HIV coinfected patients than monoinfected patients. Obtain CBC before treatment and monitor routinely during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic effects: Serious cutaneous reactions, including vesiculobullous eruptions, Stevens-Johnson syndrome, and exfoliative dermatitis, have been reported with use, with or without ribavirin therapy; discontinue with signs or symptoms of severe skin reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal effects: Gastrointestinal hemorrhage, ulcerative and hemorrhagic/ischemic colitis (may be fatal) have been observed with interferon alfa treatment; may be severe and/or life-threatening; discontinue immediately if symptoms of colitis (eg, abdominal pain, bloody diarrhea, and/or fever) develop. Colitis generally resolves within 1 to 3 weeks of discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Hepatic decompensation and death have been associated with the use of alpha interferons including Pegasys, in cirrhotic chronic hepatitis C patients; patients coinfected with HIV and receiving antiretroviral therapy have shown an increased risk. Monitor hepatic function closely during use; discontinue immediately if decompensation occurs (Child-Pugh score &gt;6) in monoinfected patients and (Child-Pugh score &ge;6, class B and C) in patients coinfected with HIV. Instruct patients to avoid alcohol; may increase hepatic effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Severe acute hypersensitivity reactions (eg, urticaria, angioedema, bronchoconstriction, anaphylaxis) have been reported; prompt discontinuation and management is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropsychiatric disorders: <b>[US Boxed Warning]: May cause or exacerbate life-threatening neuropsychiatric disorders; monitor closely; discontinue treatment with worsening or persistently severe signs/symptoms of neuropsychiatric disorders. In most cases these effects were reversible following discontinuation, but not all cases.</b> Neuropsychiatric adverse effects include depression, suicidal ideation, suicide attempt, homicidal ideation, drug overdose, and relapse of drug addiction, and may occur in patients with or without a prior history of psychiatric disorder. Avoid use in severe psychiatric disorders; use with extreme caution in patients with a history of depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ophthalmic effects: Decreased or loss of vision and retinopathy, including macular edema, optic neuritis, papilledema, retinal hemorrhages, retinal detachment (serous), cotton wool spots, and retinal artery or vein thrombosis, may occur or be aggravated during treatment; if any ocular symptoms occur during use, a complete eye exam should be performed promptly. Prior to use, all patients should have a visual exam and patients with preexisting disorders (eg, diabetic or hypertensive retinopathy) should have exams periodically during therapy. Discontinue if new or worsening ophthalmologic disorders occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: Pancreatitis, including fatal cases, has been observed with alfa interferon and ribavirin therapy. Withhold treatment for suspected pancreatitis; discontinue therapy for confirmed pancreatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary effects: May cause or aggravate dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis obliterans, interstitial pneumonitis, pulmonary hypertension, and sarcoidosis, which may result in potentially fatal respiratory failure; may recur upon rechallenge with interferons. Monitor closely. Discontinue with pulmonary infiltrates or evidence of impaired pulmonary function. Use with caution in patients with pulmonary dysfunction or a history of pulmonary disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune disease: <b> [US Boxed Warning]: May cause or exacerbate autoimmune disorders; monitor closely; discontinue treatment in patients with worsening or persistently severe signs/symptoms of autoimmune disease. In most cases these effects were reversible following discontinuation, but not all cases.</b> Thyroiditis, thrombotic thrombocytopenic purpura, immune thrombocytopenia (formerly known as idiopathic thrombocytopenic purpura), rheumatoid arthritis, interstitial nephritis, systemic lupus erythematosus, myositis, hepatitis, and psoriasis have been reported with interferon therapy; use with caution in patients with autoimmune disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with prior cardiovascular disease; hypertension, supraventricular arrhythmias, chest pain, and MI have been observed with treatment. Patients with a history of significant or unstable cardiac disease should not receive combination treatment with ribavirin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; hyper/hypoglycemia have been reported; may require adjustments in antidiabetic medications; discontinue if unable to effectively manage diabetes with medication.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatitis B: In hepatitis B patients, flares (transient and potentially severe increases in serum ALT) may occur during or after treatment; more frequent monitoring of LFTs and a dose reduction are recommended. Discontinue immediately if ALT elevation continues despite dose reduction or if increased bilirubin or hepatic decompensation occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infectious disorders: <b> [US Boxed Warning]: May cause or aggravate infectious disorders; monitor closely; discontinue treatment in patients with worsening or persistently severe signs/symptoms of infectious disorders. In most cases these effects were reversible following discontinuation, but not all cases.</b> Serious and severe infections (bacterial, viral, and fungal), some fatal, have been reported with treatment. Interferon therapy is commonly associated with flu-like symptoms, including fever; rule out other causes/infection with persistent or high fever.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ischemic disorders: <b>[US Boxed Warning]: May cause or aggravate ischemic disorders and hemorrhagic cerebrovascular events; monitor closely; discontinue treatment in patients with worsening or persistent ischemia. In most cases these effects were reversible following discontinuation, but not all cases</b>. Has been reported in patients without risk factors for stroke.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal dysfunction (CrCl &lt;30 mL/minute); dosage adjustment recommended; monitor for signs/symptoms of toxicity (dosage adjustment required if toxicity occurs).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Clinical practice chronic hepatitis B treatment guidelines do not recommend use in patients with uncontrolled seizures (AASLD [Terrault 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disorders: Use with caution in patients with preexisting thyroid disease; thyroid disorders (hyper- or hypothyroidism) or exacerbations have been reported; discontinue if unable to effectively manage with medication.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; certain adverse effects (eg, neuropsychiatric, cardiac, flu-like reactions) may be more severe.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Growth velocity (height and weight) was decreased in children with or without combination treatment with ribavirin, during the length of treatment. In clinical studies, decreases were noted in weight and height for age z-scores and normative growth curve percentiles. Following treatment, rebound growth and weight gain occurred in most patients; however, a small percentage did not. For most children with hepatitis C, posttreatment recovery in growth at 2 years posttreatment was maintained to 6 years posttreatment; no data are available on long term follow-up for children with hepatitis B. Growth should be closely monitored in children during therapy and posttreatment until growth catch-up has occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product variability: <b>Due to differences in dosage, patients should not change brands of interferon without the concurrence of their health care provider.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hepatitis C:</i> Combination therapy with ribavirin or monotherapy for the treatment of chronic hepatitis C is no longer a recommended treatment regimen (AASLD/IDSA 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hepatitis B:</i> Hepatitis B genotypes A and B are more likely to achieve HBeAg and HBsAg loss with peg-interferon than non-A/B genotypes. For patients with hepatitis B coinfected with hepatitis delta virus (HDV), pegylated interferon is the only effective therapy (AASLD [Terrault 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26047465\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibition of growth velocity in pediatric patients may occur; in clinical trials, growth suppression of &ge;15 percentiles on the normal growth curve was reported for weight in 43% of pediatric patients and for height in 25% of patients after 48 weeks of therapy. At the two-year follow-up after treatment, most children had returned to their baseline growth curve percentile; monitor growth at baseline and during therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206913\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP1A2 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206874\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=87809&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Interferons (Alfa) may increase the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegloticase: May diminish the therapeutic effect of Peginterferon Alfa-2a.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribavirin (Oral Inhalation): Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin (Oral Inhalation). Hemolytic anemia has been observed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribavirin (Systemic): Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin (Systemic). Hemolytic anemia has been observed. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telbivudine: Peginterferon Alfa-2a may enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Interferons may decrease the metabolism of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible.  If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206889\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Use with ribavirin is contraindicated in pregnant women and males whose female partners are pregnant.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Combination therapy with ribavirin may cause birth defects and/or fetal mortality; avoid pregnancy in females and female partners of male patients.</b> Pregnancy status should be assessed prior to therapy. Female patients of childbearing potential and male patients with female partners of childbearing potential must use 2 forms of contraception along with monthly pregnancy tests during therapy and for 6 months after therapy has been discontinued. If used in combination with ribavirin, all warnings related to the use of ribavirin and pregnancy and/or contraception should be followed.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Based on adverse events observed in animal reproduction studies, the manufacturer recommends that reliable contraception is used in women of childbearing potential. Alfa interferon is endogenous to normal amniotic fluid (Lebon 1982). In vitro administration studies have reported that when administered to the mother, it does not cross the placenta (Waysbort 1993).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The HHS Perinatal HIV Guidelines do not recommend that peginterferon-alfa be used during pregnancy (HHS [perinatal] 2016). Mother-to-child transmission of HCV does not occur if the woman is not viremic, therefore, HCV-infected women of childbearing potential should postpone pregnancy until therapy is complete. Treatment of HCV is not recommended for women who are already pregnant (AASLD/IDSA 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A pregnancy registry has been established for women inadvertently exposed to ribavirin while pregnant (800-593-2214).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1029870\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">The following were used during clinical trials: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &ge;5 years and Adolescents: Hematologic and biochemical assessments were made at weeks 1, 3, 5, and 8, and then every 4 weeks thereafter; TSH measured every 12 weeks; growth parameters (height, weight, percentiles on growth curve) (Schwarz, 2011) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: CBC (including hemoglobin, WBC, and platelets) and chemistries (including liver function tests and uric acid) measured at weeks 1, 2, 4, 6, and 8, and then every 4-6 weeks (more frequently if abnormal); TSH measured every 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Additionally, the following baseline values were used as entrance criteria in adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Platelet count &ge;90,000/mm<sup>3</sup> (as low as 75,000/mm<sup>3</sup> in patients with cirrhosis or 70,000/mm<sup>3</sup> in patients with HCV coinfected with HIV)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ANC &ge;1500/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Serum creatinine &lt;1.5 times ULN</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">TSH and T<sub>4</sub> within normal limits or adequately controlled</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CD4<sup>+</sup> cell count &ge;200 cells/mm<sup>3</sup> or CD4<sup>+</sup> cell count &ge;100 cells/mm<sup>3</sup>, but &lt;200 cells/mm<sup>3</sup> and HIV-1 RNA &lt;5000 copies/mL in HCV patients coinfected with HIV</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hemoglobin &ge;12 g/dL for women and &ge;13 g/dL for men in HCV monoinfected patients</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hemoglobin &ge;11 g/dL for women and &ge;12 g/dL for men in HCV patients coinfected with HIV</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Also in adults, serum HCV RNA levels (pretreatment, 12- and 24 weeks after therapy initiation, 24 weeks after completion of therapy). <b>Note:</b> Discontinuation of therapy may be considered after 12 weeks in patients with HCV (genotype 1) who fail to achieve an early virologic response (defined as &ge;2-log decrease in HCV RNA compared to pretreatment) or after 24 weeks with detectable HCV RNA (Ghany, 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Prior to treatment, pregnancy screening should occur for women of childbearing age who are receiving treatment or who have male partners who are receiving treatment. In combination therapy with ribavirin, pregnancy tests should continue monthly up to 6 months after discontinuation of therapy. Evaluate for depression and other psychiatric symptoms before and during therapy; baseline eye examination and periodically in patients with baseline disorders; baseline echocardiogram in patients with cardiac disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206869\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Alpha interferons are a family of proteins, produced by nucleated cells that have antiviral, antiproliferative, and immune-regulating activity. There are 16 known subtypes of alpha interferons. Interferons interact with cells through high affinity cell surface receptors. Following activation, multiple effects can be detected including induction of gene transcription. Interferons inhibit cellular growth, alter the state of cellular differentiation, interfere with oncogene expression, alter cell surface antigen expression, increase phagocytic activity of macrophages, and augment cytotoxicity of lymphocytes for target cells. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206885\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: 50-160 hours; increased with renal dysfunction </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 72 to 96 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15597871\" class=\"nested sp-pop-child-nested drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Clearance was nearly 4-fold lower in children 2 to 8 years of age.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206888\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Pegasys ProClick Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">135 mcg/0.5 mL (0.5 mL): $1,225.79</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mcg/0.5 mL (0.5 mL): $1,225.79</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Pegasys Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mcg/0.5 mL (0.5 mL): $1,225.79</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mcg/mL (1 mL): $1,225.79</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206891\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Optipeg-A (BD);</li>\n      <li>Pegasys (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CR, CU, CY, CZ, DE, DK, DO, EC, EE, ES, ET, FI, FR, GB, GR, GT, HK, HN, HR, HU, IE, IL, IS, IT, JO, JP, KR, KW, LB, LK, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, UY, VE, VN);</li>\n      <li>Pegasys PFS (KR);</li>\n      <li>Pegferon (BD);</li>\n      <li>Peghasis (UA);</li>\n      <li>Pegin (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Practice Bulletin No. 86: &ldquo;Viral Hepatitis in Pregnancy,&rdquo; <i>Obstet Gynecol</i>, 2007, 110(4):941-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/17906043/pubmed\" target=\"_blank\" id=\"17906043\">17906043</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo; <i>Am J Health-Syst Pharm</i>, 2007, 64(16):1711-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/17687059/pubmed\" target=\"_blank\" id=\"17687059\">17687059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ghany MG, Nelson DR, Strader DB, et al, &quot;An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases,&quot; <i>Hepatology</i>, 2011, 54(4):1433-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/21898493/pubmed\" target=\"_blank\" id=\"21898493\">21898493</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ghany MG, Strader DB, Thomas DL, et al, &ldquo;Diagnosis, Management and Treatment of Hepatitis C: An Update,&rdquo; <i>Hepatology</i>, 2009, 49(4):1335-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/19330875/pubmed\" target=\"_blank\" id=\"19330875\">19330875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lebon P, Girard S, Thepot F, et al, &ldquo;The Presence of Alpha-Interferon in Human Amniotic Fluid,&rdquo; <i>J Gen Virol</i>, 1982, 59(Pt 2):393-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/6176680/pubmed\" target=\"_blank\" id=\"6176680\">6176680</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murray KF, Rodrigue JR, Gonz&aacute;lez-Peralta RP, et al, &quot;Design of the PEDS-C trial: Pegylated Interferon &plusmn; Ribavirin for Children With Chronic Hepatitis C Viral Infection,&quot; <i>Clin Trials</i>, 2007, 4(6):661-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/18042575/pubmed\" target=\"_blank\" id=\"18042575\">18042575</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,&rdquo; April 29, 2009, 1-90. Available at <a href=\"http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al, &quot;The Combination of Ribavirin and Peginterferon Is Superior to Peginterferon and Placebo for Children and Adolescents With Chronic Hepatitis C,&quot; <i>Gastroenterology</i>, 2011, 140(2):450-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/21036173/pubmed\" target=\"_blank\" id=\"21036173\">21036173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Waysbort A, Giroux M, Mansat V, et al, &ldquo;Experimental Study of Transplacental Passage of Alpha Interferon by Two Assay Techniques,&rdquo; <i>Antimicrob Agents Chemother</i>, 1993, 37(6):1232-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pegylated-interferon-peginterferon-alfa-2a-pediatric-drug-information/abstract-text/8328774/pubmed\" target=\"_blank\" id=\"8328774\">8328774</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 87809 Version 78.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709197\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F206899\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F206900\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1029834\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1029863\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F206881\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F206867\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874941\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1029868\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F206895\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1029835\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F206924\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F206886\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F206870\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26047465\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F206913\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F206874\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F206889\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1029870\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F206869\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F206885\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Pediatric Considerations\" href=\"#F15597871\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F206888\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F206891\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/87809|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pegylated-interferon-peginterferon-alfa-2a-drug-information\" class=\"drug drug_general\">Pegylated interferon (peginterferon) alfa-2a: Drug information</a></li><li><a href=\"topic.htm?path=pegylated-interferon-peginterferon-alfa-2a-patient-drug-information\" class=\"drug drug_patient\">Pegylated interferon (peginterferon) alfa-2a: Patient drug information</a></li></ul></div></div>","javascript":null}